Andrew Wasmuth, Brooklyn, NY (US); Donald W. Landry, New York, NY (US); Shixian Deng, White Plains, NY (US); Banavara L. Mylari, East Lyme, CT (US); Ravichandran Ramasamy, Ardsley, NY (US); and Ann Marie Schmidt, Franklin Lakes, NJ (US)
Assigned to THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, New York, NY (US)
Filed by The Trustees of Columbia University in the City of New York, New York, NY (US)
Filed on May 28, 2020, as Appl. No. 16/886,165.
Application 14/541,365 is a division of application No. 13/742,573, filed on Jan. 16, 2013, granted, now 8,916,563, issued on Dec. 23, 2014.
Application 16/886,165 is a continuation of application No. 16/598,119, filed on Oct. 10, 2019.
Application 16/598,119 is a continuation of application No. 15/489,834, filed on Apr. 18, 2017, abandoned.
Application 15/489,834 is a continuation of application No. 14/541,365, filed on Nov. 14, 2014, granted, now 9,650,383, issued on May 16, 2017.
Application 13/742,573 is a continuation in part of application No. PCT/US2011/044038, filed on Jul. 14, 2011.
Claims priority of provisional application 61/365,098, filed on Jul. 16, 2010.
Prior Publication US 2020/0289512 A1, Sep. 17, 2020
1. A method for inhibiting aldose reductase activity in a subject, comprising administering to a subject with neuropathy a therapeutically effective amount of a compound of formula (I)
wherein,
R1 is H or (C1-C6)-alkyl;
X1 is N;
X2 is CH;
X3 is CH;
X4 is N;
Y is C═O, C═S, C═NH, or C═N(C1-C4)-alkyl;
Z is
A1 is S;
A2 is N; and
R7 through R10 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C1-C4)-alkoxy, (C1-C4)-alkylthio, (C1-C4)-alkylsulfinyl, or (C1-C4)-alkylsulfonyl; or two of R7 through R10 taken together are (C1-C4)-alkylenedioxy;
or a pharmaceutically acceptable salt or solvate thereof.
